How Does Health Technology Assessment of Personalized Medicine for Non-Small Cell Lung Cancer Differ in France, Germany, and England?

Value in Health - United Kingdom
doi 10.1016/j.jval.2016.09.2367
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Improving Molecular Testing and Personalized Medicine in Non-Small-Cell Lung Cancer in Ontario

Current Oncology
Oncology
2017English

Patient-Derived Xenograft Models of Non-Small Cell Lung Cancer and Their Potential Utility in Personalized Medicine

Frontiers in Oncology
Cancer ResearchOncology
2017English

How Do Patient and Hospital Features Influence Outcomes in Small-Cell Lung Cancer in England?

British Journal of Cancer
Cancer ResearchOncology
2011English

Using Stem Cell Biology to Design Precision Medicine for Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2016English

Patient Count Forecasts of Advanced Non-Small Cell Lung Cancer: Results From the UK, Germany, France, Italy and Spain (Eu-5)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Personalized Medicine Tackles Clinical Resistance: Alectinib in ALK-Positive Non-Small Cell Lung Cancer Progressing on First-Generation ALK Inhibitor

Clinical Cancer Research
Cancer ResearchOncology
2016English

Recent Trends in Resection Rates Among Non-Small Cell Lung Cancer Patients in England

Thorax
PulmonaryRespiratory Medicine
2012English

Non-Small Cell Lung Cancer

English

Pcn338 - The Evolution of Treatment Algorithms in Non-Small-Cell Lung Cancer: Implications for Reimbursements in England

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy